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ABSTRACT 50 
Optimal dosing of gentamicin in neonates is still a matter of debate despite its common use. 51 
We identified gentamicin dosing regimens from 8 international guidelines and 7 Swiss 52 
Neonatal Intensive Care Units. Dose per administration, dosing interval, total daily dose and 53 
demographic characteristics between guidelines were compared. There was considerable 54 
variability with respect to dose (4 to 6 mg/kg), dosing interval (24 h to 48 h), total daily dose 55 
(2.5 to 6 mg/kg/day) and patient demographic characteristics which were used to calculate 56 
individualized dosing regimens. A model-based simulation study in 1071 neonates was 57 
performed to determine achievement of efficacious peak gentamicin concentrations according 58 
to predefined minimum inhibitory concentrations (MICs) (Cmax / MIC ≥ 10) and safe trough 59 
concentrations (Cmin ≤ 2 mg/L) with recommended dosing regimens. MIC targets of 0.5 and 1 60 
mg/L were used. Dosing optimization was performed giving priority to the first day of 61 
treatment and with the goal of simplifying dosing. Current gentamicin neonatal guidelines, 62 
achieve effective peak concentrations if MIC is 0.5 mg/L but not for MICs ≥ 1 mg/L. Model-63 
based simulations indicate that to attain peak gentamicin concentrations ≥ 10 mg/L, a dose of 64 
7.5 mg/kg should be administered using an extended dosing interval regimen. Trough 65 
concentrations ≤ 2 mg/L can be maintained with a dosing interval of 36 to 48 hours in 66 
neonates according to gestational and postnatal age. For treatment beyond 3 days, therapeutic 67 
drug monitoring is advised to maintain adequate serum concentrations. 68 
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INTRODUCTION 69 
In 2015, about 1.4 million children died worldwide of infections such as pneumonia or 70 
sepsis/meningitis in the first 5 years of their life, most of them during the neonatal period (1). 71 
The most common cause of Gram-negative early-onset neonatal sepsis (EONS) is Escherichia 72 
coli (2). Other Gram-negative and Gram-positive microorganisms are involved in early or late 73 
neonatal sepsis including Klebsiella spp. and Pseudomonas aeruginosa (3, 4). By virtue of 74 
their bactericidal activity and their low costs, aminoglycosides, such as gentamicin, remain 75 
the first-line therapy in combination with a β-lactam antibiotic for confirmed or suspected 76 
neonatal sepsis (5, 6). However, gentamicin has a narrow therapeutic index and optimal, 77 
personalized dosing in neonates is still debated (7). Based on in vitro studies, optimal 78 
gentamicin efficacy is associated with a plasma peak concentration over minimum inhibitory 79 
concentration (MIC) ratio (Cmax/MIC) ≥ 8 – 10 (8-10). It has been suggested that the area 80 
under the curve (AUC) over MIC ratio (AUC/MIC) could represent another 81 
pharmacodynamic predictor of efficacy of aminoglycosides (11). Achieving this optimal 82 
efficacy in vivo needs to be balanced against nephrotoxicity and ototoxicity associated with 83 
high trough concentrations of gentamicin. Nephrotoxicity of aminoglycosides affect both the 84 
glomerular and tubular functions (12). While nephrotoxicity is generally temporary and 85 
reversible upon treatment discontinuation, ototoxicity might be permanent (13, 14). It has 86 
been suggested that trough plasma concentrations of gentamicin should not exceed 1 to 2 87 
mg/L to minimize potential toxic effects (15, 16, 17). Further, it has been reported that 88 
multiple daily dosing and long duration of treatment are more likely to increase the risk of 89 
toxicity (18).  90 
 91 
In the neonatal population, development and organ maturation is a dynamic process that 92 
influences gentamicin pharmacokinetics. Variability in kidney function and body composition 93 
in particular is responsible for the large interpatient variability in clearance and volume of 94 
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distribution of gentamicin in this population. Clearance of gentamicin is indeed almost 95 
entirely dependent on glomerular filtration (19). Nephrogenesis is completed after 34-35 96 
weeks of gestation and preterm neonates present a lower glomerular filtration rate (GFR) as 97 
compared to late preterm and term neonates (20). Birth is marked by major hemodynamic 98 
changes that are responsible for a rapid postnatal increase in GFR in all neonates (21-24). 99 
Gentamicin distribution is mostly limited to the extracellular fluid compartment. Neonates 100 
have a body water content that is proportionally larger compared to adults and older children. 101 
Therefore, an increased gentamicin volume of distribution is often observed and explains why 102 
a relatively higher dose per kilogram in neonatal dosing is recommended in order to achieve 103 
an effective peak concentration (25).  104 
 105 
Pharmacokinetic (PK) understanding of gentamicin in neonates has increased throughout the 106 
years. However, this newly acquired knowledge has resulted in many different gentamicin 107 
dosing regimens rather than one consistent, optimal dosing regimen for use in daily clinical 108 
care (26). Pharmacometric analyses, including pharmacokinetic-pharmacodynamic (PK/PD) 109 
modeling and simulation, facilitate evaluation of existing dosing regimens with respect to 110 
target attainment and can provide a quantitative rationale for optimizing and personalizing 111 
dosing approaches in neonates (27, 28).  112 
 113 
The key objectives of this study were to (1) assess the variability in dosing of gentamicin in 114 
international guidelines and Swiss Neonatal Intensive Care Units (NICUs), (2) evaluate and 115 
compare target achievement of current dosing recommendations with respect to efficacy and 116 
safety and (3) provide a quantitative rationale for an optimal, personalized gentamicin dosing 117 
approach to be implemented in a high resource setting such as Swiss NICUs in light of 118 
currently relevant MIC breakpoints.  119 
 120 
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RESULTS 121 
Variability in National and International Guidelines 122 
Considerable variability in dosing regimen recommendations provided by international 123 
guidelines and in Swiss NICUs was observed with respect to dose (4 to 6 mg/kg), dosing 124 
interval (24 h to 48 h), total daily dose (2.5 to 6 mg/kg/day) and patient characteristics’ 125 
(qualitative and quantitative) which are used to individualize dosing regimens (Table 1). 126 
While two Swiss NICUs did not use any demographic characteristics for a priori selection of 127 
dosing regimens, most guidelines suggested individualized dosing regimens based on a single 128 
or a combination of patient demographic characteristics. Gestational age (GA) combined with 129 
postnatal age (PNA) was the most frequently observed regimen. Three different dosing 130 
intervals were observed (24 h, 36 h and 48 h), with the longest interval used in the most 131 
preterm neonates. Although the same demographic characteristics were mostly used, the cut-132 
off values to define the patient subgroups varied between recommendations. The variability in 133 
gentamicin dosing used in Swiss NICUs and proposed in international guidelines is illustrated 134 
for two typical patients (preterm and term neonates) at different postnatal ages in Table 2.  135 
 136 
Achievement of Efficacious and Safe Gentamicin Exposure 137 
Considering achieving target gentamicin exposure in at least 90% of neonatal patients (90% 138 
probability of target attainment, PTA) as an appropriate outcome, simulations suggested that 139 
all recommendations were adequate in terms of efficacy for pathogens with an MIC of 0.5 140 
mg/L, but appeared inadequate for pathogens with an MIC of 1.0 mg/L (Table 1). Gentamicin 141 
peak concentrations ≥ 5 mg/L were achieved in > 96% of neonates whereas a peak 142 
concentration ≥ 10 mg/L was found in < 60% of neonates. Recommendations were successful 143 
in maintaining trough concentrations < 2 mg/L in more than 95% of the patients, with one 144 
exception (Center 7).  145 
 146 
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Dosing Optimization  147 
Efficacy target attainment 148 
None of the reviewed guidelines was an obvious candidate for optimal and simplified 149 
gentamicin dosing. Therefore, dosing optimization was undertaken for MICs of 0.5 and 1 150 
mg/L (Cmax ≥ 5 mg/L and ≥ 10 mg/L, respectively). A dose per administration of 4 mg/kg 151 
appeared sufficient to achieve a Cmax concentration of at least 5 mg/L with PTA ≥ 96%. 152 
Simulations suggest that the dose needs to be increased to 7.5 mg/kg to achieve target peak 153 
concentrations ≥ 10 mg/L in ≥ 90% neonates (Figure 1). 154 
 155 
Safety target attainment  156 
First dose. For a dosing regimen of 7.5 mg/kg, only 6% of the patients would present trough 157 
concentrations ≥ 2 mg/L after the dosing interval has been increased to 36 hours for all 158 
neonates (Table S1). However, it was observed that neonates with PNA < 7 days showed 159 
more frequently high trough concentrations (9%) than neonates with PNA ≥ 7 days (4%) (data 160 
not shown). If neonates with PNA < 7 days were dosed every 48 hours only 1% reached these 161 
high concentrations (Table 3).  162 
After one week of treatment. A dosing regimen of 7.5 mg/kg every 36 hours for neonates 163 
with PNA ≥ 7 days and every 48 hours for those with PNA < 7 days would result in some 164 
accumulation after one week of treatment in the oldest subgroup (PNA ≥ 7 days), with 13% of 165 
them reaching trough concentrations ≥ 2 mg/L (data not shown). Additional subgroup 166 
stratification for patients in the oldest subgroup (PNA ≥ 7 days) who received 7.5 mg/kg 167 
every 36 hours if their GA ≥ 28 weeks and every 48 hours if their GA ≤ 28 weeks, would 168 
allow target achievements of trough concentrations below the predefined safety threshold in 169 
both groups in more than 90% of neonates (Table 3). Neonates with PNA < 7 and GA ≤ 28 170 
weeks would require a dosing interval of 60 hours. However, with a 48 hours dosing interval, 171 
93% would show trough concentrations < 2 mg/L after the second dose (96 hours after the 172 
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start of treatment while most treatment courses will be discontinued at 72 hours) (data not 173 
shown). Similar subgroup stratification, based on PNA and GA, were required for a dose of 4 174 
mg/kg (Table 3). 175 
 176 
In the scope of simplifying the dosing regimen of gentamicin in high resource settings, a 177 
standard dose of 7.5 mg/kg to achieve an effective exposure (Cmax / MIC ≥ 10) is favored 178 
from the first dose, irrespective of any demographic factors, when an MIC of 1 mg/L is 179 
considered. Individual dosing intervals for the following doses from 36 to 48 hours are 180 
suggested according to PNA and GA (Table 3 & Figure 2). TDM should be considered for 181 
treatment periods beyond 3 days to fine-tune dosing intervals at the individual level, 182 
particularly in the most preterm neonates.  183 
 184 
Sensitivity analysis. The proposed dosing regimen would not suffice in ascertaining a trough 185 
concentration < 1 mg/L in ≥ 90% of the patients (Table 3). For an initial gentamicin dose of 186 
7.5 mg/kg, 90% of the patient would achieve a trough concentration < 1mg/L after one week 187 
of treatment by increasing the dosing interval by 72 hours (or more) for patients with GA ≤ 28 188 
weeks and by 48 hours or 60 hours for patients with GA > 28 and PNA < 7 days or PNA ≥ 7 189 
days, respectively. Following an initial dose of 4 mg/kg, dosing intervals should be increased 190 
by 12 hours for each subgroup except for patients PNA < 7 days and GA ≤ 28 weeks that 191 
would require a dosing interval of 60 hours (data not shown). Predicted concentrations and 192 
area under the curve (AUC) distributions are provided in the supplemental content (Table S2, 193 
Figures S1-S3). 194 
 195 
DISCUSSION 196 
Considerable variability in gentamicin dosing recommendation is observed in current 197 
international guidelines as well as in Swiss NICUs, in agreement with other studies (30). 198 
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According to simulations of neonatal exposure, results suggest that a dose of 4 mg/kg, as 199 
frequently used in current recommendations, would be sufficient when an MIC breakpoint of 200 
0.5 mg/L is considered. A higher MIC breakpoint of 1 mg/L requires a dose of 7.5 mg/kg to 201 
achieve efficacious gentamicin exposures in at least 90% of treated neonates. Maintaining 202 
trough concentrations ≤ 2 mg/L requires a dosing interval of 36 to 48 hours in neonates 203 
according to postnatal age and gestational age. 204 
 205 
Observed sources of variation in Swiss and international guidelines include differences in 206 
dose per administration, dosing interval, total daily dose and/or patient characteristics used for 207 
dose individualization. Complex dosing recommendations for personalized treatment increase 208 
the risk of prescription errors and are factors triggering suboptimal patient management (31, 209 
32), highlighting the potential benefit of using dosing harmonization and simplification for a 210 
large number of patients. Variation between recommendations did not result in improved 211 
efficacy and/or safety of gentamicin use. All recommendations managed to achieve 212 
gentamicin peak concentrations ≥ 5 mg/L (MIC of 0.5 mg/L), but failed to achieve peak 213 
concentrations of ≥ 10 m/L (MIC of 1 mg/L) in a high proportion of neonates. Except for one 214 
recommendation, all lead to a relatively small proportion of neonates (< 5 %) with potentially 215 
unsafe trough levels ≤ 2 mg/L. 216 
 217 
It is likely that guidelines were established considering lower MICs and therefore lower peak 218 
concentrations. Dosing strategies should ideally rely on individual MICs, but in NICUs, the 219 
majority of neonates are treated empirically at the stage when infection cannot yet be 220 
definitively confirmed and in many cases, it cannot be identified. Treatment should therefore 221 
target the most likely and the most virulent pathogens involved in neonatal infections and 222 
MIC targets are based upon standard MIC breakpoints from antimicrobial susceptibility 223 
testing databases (33, 34). By using this approach, it is possible that the MIC breakpoint used 224 
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is higher than observed gentamicin MIC in individual patients’ isolates (35). In this study, 225 
MICs up to 1 mg/L are addressed. While MICs for many Enterobacteriaceae were 226 
historically 0.5 mg/L, MICs of 1 mg/L are increasingly observed, especially for the spectrum 227 
of pathogens encountered in late neonatal onset sepsis (Pseudomonas spp., Klebsiella spp.) 228 
(36). EUCAST sensitivity breakpoint for Escherichia coli is currently 2 mg/L, although this is 229 
rather rarely observed in Switzerland (37). In addition, rates of multidrug resistance of Gram-230 
negative infections to empiric treatment are increasing, especially in resource limited settings 231 
where MICs up to 4 mg/L are now encountered (Table S3) (33). Accordingly, peak 232 
concentrations of 20 - 40 mg/L would be required, but are very challenging to achieve (Figure 233 
1) and could result in inacceptable toxicity.  234 
 235 
The pre-defined exposure target for efficacy was set to Cmax/MIC ≥ 10. This is more 236 
conservative compared to a ratio of 8 (9, 38), but was preferred as Cmax/MIC ratio of 10 was 237 
associated with peak efficacy according to a pooled analysis of the 1980s data reported by 238 
Turnidge et al. (39), and Cmax/MIC ≥ 10 ratio has been shown to be necessary if deep tissue 239 
penetration for infections is required (40-42). It is also reported that attainment of a PD target 240 
(Cmax/MIC > 10) within 48 h of therapy is associated with an early therapeutic response (39). 241 
In addition, the impact of the immature neonatal immune system on the appropriate efficacy 242 
target is unknown, and this slightly higher target might be more suitable in this population 243 
(43).  244 
 245 
Finally, although PTA ≥ 90% was considered as an appropriate outcome, the acceptable level 246 
of PTA is still under debate with values from ranging 90% to 99% (44). However, the 247 
definition of a target PTA has not been applied in a majority of previous gentamicin studies 248 
and dosing recommendations from previous analysis are based on much lower proportions of 249 
infants achieving target exposure (45-53).  250 
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 251 
As for many drugs, solid trial data supporting the use of specific doses associated with good 252 
clinical outcome in vivo in this vulnerable population are lacking. As a result, current dosing 253 
recommendations for gentamicin are variable and often complex. More evidence-based 254 
dosing recommendations are required (26). However, trials for (suspected) infections are 255 
difficult to design due to endpoint definitions, the low number of actual confirmed infections 256 
in the neonatal population and obvious ethical reasons. Dosing optimization and possibly 257 
simplification can benefit from pharmacometric modeling and simulations techniques. We 258 
have used exposure simulations in 1071 neonatal patients leveraging an existing neonatal 259 
gentamicin PK model to identify dosing regimens with a high probability of reaching pre-260 
defined efficacy and safety targets in a high proportion of patients. Priority was given to 261 
optimizing and simplifying the first dose of gentamicin in order to maximize the 262 
microorganism clearance as early as possible during infection (hit hard and hit fast paradigm) 263 
(54). 264 
 265 
Combination of higher efficacy criteria and higher PTA set in this study might appear 266 
conservative as compared to previous studies, but are in line with the current methodology 267 
used in simulation and dosing optimization for other antibiotics and with MICs encountered in 268 
NICUs (55-57). Presumably, this explains why our simulations suggest a higher dose (7.5 269 
mg/kg) as compared to current international and local guidelines. It is acknowledged that a 270 
large number of patients are exposed to gentamicin while not having a true infection, putting 271 
them at risk of adverse events with no benefits. However, effective initial therapy to cover 272 
pathogens which are difficult to treat is essential for those infants with a true infection to 273 
minimize adverse outcome due to the infection (2).  274 
Nephro- and oto-toxicity do not seem to be associated with peak concentrations (58), but 275 
rather with drug accumulation and prolonged treatment (59). Though, the safety consequences 276 
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of higher peak concentration to target higher MICs are unknown. Nevertheless, toxicity 277 
incidence remains low in the pediatric population and is lower than the rates reported in 278 
adults, in particular when extended dosing intervals are used (60). To maintain trough 279 
concentrations ≤ 2 mg/L with a dose of 7.5 mg/kg, the dosing interval should be extended to 280 
36 – 48 hours. This dosing regimen would also ensure trough concentrations < 1 mg/L in the 281 
majority of patients (> 82%), a target sometimes used as a more stringent surrogate for safety. 282 
Thomson et al. investigated the daily intramuscular administration of an 8 mg/kg gentamicin 283 
dose and trough concentrations < 2 mg/L were observed (61). Lopez et al. investigated 284 
extended intervals (24 and 36 hours) after high gentamicin doses (8 mg/kg) and no 285 
nephrotoxicity was observed in this study, although gentamicin was not administered for 286 
prolonged periods (no longer than 5 days) (58). Additionally, it was found that a gentamicin 287 
dose of 8 mg/kg provided near 100% probability of achieving adequate peak concentrations > 288 
16 mg/L (for a population that included children up to 4 years old) (58). In a study involving 289 
newborns receiving a 6 mg/kg gentamicin dose over various intervals ranging from 24 to 48 290 
hours, trough concentrations ≥ 2 mg/L were observed in only 6% of all treatment episodes. 291 
No evidence for ototoxicity was observed and potential nephrotoxicity was not assessed in 292 
any detail (21). 293 
 294 
Since the first hours of infection are crucial, administration of antibiotics within one hour of 295 
identification of sepsis is recommended (62). Therapeutic drug monitoring is recommended 296 
for longer courses to evaluate the necessity of adjusting dosing interval on any individual 297 
basis (63). Considering that trough gentamicin TDM is cumbersome in neonates and that 298 
steady-state definition in neonates is not applicable, a Bayesian-based TDM approach 299 
allowing opportunistic TDM at the time of routine blood tests based on one concentration 300 
measurement would present numerous advantages (19). For a large proportion of patients, 301 
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treatment will be discontinued after 48 - 72 hours and most of them would receive only one to 302 
two doses and therefore would not require TDM, limiting the burden of blood sampling. 303 
 304 
Another important constraint concerns the selection of the model used to investigate 305 
gentamicin drug exposure in neonatal patients in this simulation study. The choice of the most 306 
robust model (Germovsek et al. model) was evaluated with respect to the population on which 307 
the model was built, the data used for model development (number of centers, prospective 308 
collection, number of subjects and concentrations measurements), the relevance of covariate 309 
effects included in the model, and the assessment of the predictive performance of the model. 310 
Simulation results were also compared with those obtained with the two other published 311 
models to avoid any systematic bias in the prediction. This sensitivity test yielded similar 312 
results as shown in Table S4 and Figure S6.      313 
 314 
CONCLUSION 315 
This simulation study in 1071 neonatal patients suggests that a gentamicin dose per 316 
administration of 7.5 mg/kg is optimal to achieve an efficacious peak concentration 317 
corresponding to an MIC of 1.0 mg/L in 90% of neonates. To ensure trough concentration 318 
associated with less toxicity during the first 60 days of life, dosing intervals of 36 to 48 hours 319 
are recommended, depending on PNA and GA. Therapeutic drug monitoring should be 320 
considered for treatment longer than three days to adjust and individualize dosing intervals 321 
and avoid potentially harming trough concentrations of gentamicin. This study also highlights 322 
the lack of consensus on magnitude of the targeted PK/PD index, desirable PTA to achieve 323 
and need for models to address the immaturity of the immune system of neonates. Our 324 
findings stress the urgent need for prospective clinical evaluations of efficacy and safety 325 
outcomes with gentamicin. 326 
 327 
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MATERIALS & METHODS 328 
Data Collection Dosing Regimens 329 
Gentamicin dosing regimens were collected from eight international guidelines (Frank Shann, 330 
British National Formulary for Children, Nelson Textbook of Pediatrics, Neonatal Formulary 331 
7
th
 edition, The Blue Book, Lexicomp Pediatric & Neonatal Dosage Handbook, The Red 332 
Book and Neofax) (17, 29, 64-69) and seven Swiss NICUs (Aarau, Bern, Chur, Geneva, 333 
Lausanne, St Gallen and Zurich). Variables used for the selection of a priori dosing regimens 334 
were compared i.e. dose per administration, dosing interval, total daily dose and demographic 335 
characteristics. 336 
 337 
Simulation of Gentamicin Exposure 338 
Demographic data 339 
Simulation of individual gentamicin exposure used real demographic data from the Antibiotic 340 
Resistance and Prescribing in European Children (ARPEC) (70, 71) point prevalence study, 341 
and including only European neonates with the complete set of the following characteristics: 342 
gestational age, birth weight, current weight and postnatal age. As all data were on neonates 343 
and infants treated for suspected infection, the skewed distribution of demographic 344 
characteristics in this population likely reflects the epidemiology of suspected sepsis at birth 345 
(Table 4). Postmenstrual age was computed as the sum of gestational age and postnatal age. 346 
The final dataset included 1071 patients with real-life demographic data and their correlation.   347 
 348 
Model selection 349 
Multiple population PK models for gentamicin in neonates have been published and were 350 
recently reviewed (28). The search strategy provided by Wilbaux et al. was applied and 351 
extended until February 2017. Criteria for model selection consisted of:  (i) data on which the 352 
model was developed includes the population of interest i.e. term and preterm neonates aged 353 
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up to at least 60 days, (ii) robustness of data used for model development (number of centers, 354 
prospective collection, number of subjects and concentrations measurements), (iii) relevance 355 
of covariate effects included in the model with respect to developmental and maturational 356 
changes in neonates and (iv) assessment and documentation of the predictive performance of 357 
the model.  358 
 359 
The population PK model of Germovsek et al. (19) was preferred over others (45-53, 58, 61, 360 
72-78) for the following reasons: (i) this model was developed with rich data collected 361 
prospectively in three large previously conducted studies (45, 75), (ii) the analysis dataset  362 
consisted of data from 205 neonates providing 1325 gentamicin serum concentrations, (iii) 363 
appropriate representation of the target population with gestational age, postnatal age and 364 
weight ranging from 23.3 - 42.3 weeks, 1 – 78 days and 2.03 – 5.05 kg, respectively. In this 365 
analysis, data were best described by a 3-compartmental model with linear elimination. 366 
Clearance and volume of distribution were scaled allometrically to body weight. A maturation 367 
function incorporating PMA (79) in addition to PNA and serum creatinine concentration 368 
(SCr) influenced drug clearance.  369 
Since there were no SCr values available in the ARPEC dataset used for simulations, SCr was 370 
set to typical values in this neonatal population as proposed by Germovsek et al. (19) i.e. the 371 
measured SCr concentration/typical value of SCr concentration ratio was set to 1. A deviation 372 
of SCr concentration to 60 μmol/L from a typical SCr concentration 70 μmol/L has only a 373 
marginal effect on drug clearance in the applied model (clearance 2% lower). Linear PK was 374 
assumed for the total range of doses tested and the weight remained constant during the first 375 
week of treatment. Gentamicin exposures associated with dosing regimens of interest were 376 
simulated in all neonatal patients in the available dataset (n = 1071). Each patient was 377 
simulated once and peak concentrations were retrieved at 1 hour post dose, i.e. 0.5 hour 378 
following the end of infusion. 379 
16 
 
 380 
Evaluation Steps 381 
Germovsek et al. evaluated their model by bootstrap and visual predictive checks as well as 382 
against an external dataset (163 neonates, prospective collection from five hospitals). Model 383 
trough concentrations predicted from their model and from literature (45, 46, 49, 50, 58, 72-384 
76) were compared using their external evaluation dataset. The predicted trough 385 
concentrations were the least biased for their model (19). We also compared predicted 386 
gentamicin exposure with the applied model to two other published models (45, 63) using our 387 
final dosing recommendation. 388 
 389 
Model-based simulations for gentamicin dosing up to 7 days were performed with the 390 
software package NONMEM® (version 7.3.0; ICON Development Solutions, Ellicott City, 391 
MD), data evaluation and visual representations were performed with R (version 3.1.2; R 392 
Development Core Team, Vienna, Austria, http://www.r-project.org).  393 
 394 
Pharmacodynamic surrogates 395 
Cmax/MIC > 10 ratio was chosen as the PD surrogate. Gentamicin concentrations ≥ 5 mg/L 396 
and ≥ 10 mg/L, corresponding to MIC breakpoints of 0.5 mg/l and 1.0 mg/L respectively, 397 
were set as peak targets. A trough concentration ≤ 2 mg/L was set as an appropriate target 398 
minimizing toxic effects. The proportion of patients reaching the targets for efficacy and 399 
safety surrogates were computed after the first dose (first dose study on day 1) and after one 400 
week of treatment (last dose on study day 7), and defined as the probability of target 401 
achievement (PTA). The aim was to select a dosing regimen leading to a PTA ≥ 90% within 402 
the predefined targets for efficacy and safety (44).  403 
 404 
Gentamicin Dosing Optimization  405 
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A stepwise approach was applied to identify an optimal dosing regimen. As a first step, the 406 
minimal dose per administration (mg/kg) that achieved target peak concentrations was 407 
selected (target attainment with respect to efficacy). The following escalating single doses per 408 
body weight were simulated: 4, 5, 6, 7, 7.5, 8, 10, 12, 14 and 16 mg/kg. As a second step, 409 
adequate dosing intervals were evaluated for the selected dose to avoid accumulation and 410 
maintain target trough concentrations ≤ 2 mg/L (target attainment with respect to safety). The 411 
following dosing intervals were evaluated in the simulation study: 24 hours, 36 hours, 48 412 
hours and 72 hours. As a third step, neonatal patients were categorized into subgroups to test 413 
whether dosing could be further optimized and personalized in neonates with dose 414 
adjustments based on patient characteristics (e.g. various doses based on PNA categories). A 415 
sensitivity analysis was performed for a trough concentration ≤ 1 mg/L. 416 
 417 
The results were retrieved after the first dose and one week of treatment but priority was 418 
given to achieving efficacious and safe exposure after the first dose, considering that (i) 419 
accurate treatment within the first hours of infection is crucial (54), (ii) treatment will be 420 
discontinued within 72 hours in a majority of neonatal patients for non-confirmed infection or 421 
switched to a more targeted therapy for confirmed infection, (iii) a large proportion of treated 422 
neonatal patients are expected to undergo therapeutic drug monitoring to ensure efficacious 423 
and safe exposures beyond the first 2-3 days of treatment in high income countries.  424 
 425 
ACKNOWLEDGMENTS 426 
This project is part of the national SwissPedDose project for harmonizing dosing in neonates, 427 
infants, and children supported by the Swiss Federal Public Health Office (BAG) which 428 
supports the research group of Paediatric Pharmacology and Pharmacometrics at UKBB. 429 
We thank all physicians, nurses and medical personnel from the 7 hospitals that helped us and 430 
allowed us the data acquisition about drug dosing regimens.  We like to thank the members of 431 
18 
 
the expert committee of the SwissPedDose project in addition to those listed as authors: Eric 432 
Giannoni, (Clinic of Neonatology, Department Woman-Mother-Child, Lausanne University 433 
Hospital, Lausanne, Switzerland), Thomas M. Berger (Board Member, Swiss Society of 434 
Neonatology, Luzern, Switzerland), René Glanzmann (Division of Neonatology, University 435 
of Basel Children’s  Hospital, Basel, Switzerland). We thank Prof. Herman Goossens and Ms 436 
Ann Versporten from the University of Antwerp and the ARPEC project group for provision 437 
of the ARPEC dataset. 438 
  439 
19 
 
REFERENCES 440 
1. Liu L, Oza S, Hogan D, Chu Y, Perin J, Zhu J, Lawn JE, Cousens S, Mathers C, Black RE. 2016. 441 
Global, regional, and national causes of under-5 mortality in 2000–15: an updated systematic 442 
analysis with implications for the Sustainable Development Goals. Lancet (London, England) 443 
388:3027-3035. 444 
2. Kent A, Kortsalioudaki C, Monahan IM, Bielicki J, Planche TD, Heath PT, Sharland M. 2016. 445 
Neonatal gram-negative infections, antibiotic susceptibility and clinical outcome: an 446 
observational study. Archives of Disease in Childhood - Fetal and Neonatal Edition 101:F507. 447 
3. Simonsen KA, Anderson-Berry AL, Delair SF, Davies HD. 2014. Early-Onset Neonatal Sepsis. 448 
Clinical Microbiology Reviews 27:21-47. 449 
4. Cortese F, Scicchitano P, Gesualdo M, Filaninno A, De Giorgi E, Schettini F, Laforgia N, 450 
Ciccone MM. 2016. Early and Late Infections in Newborns: Where Do We Stand? A Review. 451 
Pediatrics & Neonatology 57:265-273. 452 
5. Cantey JB, Wozniak PS, Sanchez PJ. 2015. Prospective surveillance of antibiotic use in the 453 
neonatal intensive care unit: results from the SCOUT study. Pediatr Infect Dis J 34:267-272. 454 
6. World Health Organization. 2013. Pocket book of hospital care for children: guidelines for 455 
the management of common childhood illnesses. World Health Organization. 456 
7. Chattopadhyay B. 2002. Newborns and gentamicin—how much and how often? Journal of 457 
Antimicrobial Chemotherapy 49:13-16. 458 
8. Allegaert K, Veerle C, van den Anker JN. 2015. Dosing Guidelines of Aminoglycosides in 459 
Neonates: A Balance Between Physiology and Feasibility. Current Pharmaceutical Design 460 
21:5699-5704. 461 
9. Kirby WMM, Standiford HC. 1969. Gentamicin: in vitro studies. The Journal of infectious 462 
diseases:361-363. 463 
10. Lacy MK, Nicolau DP, Nightingale CH, Quintiliani R. 1998. The pharmacodynamics of 464 
aminoglycosides. Clinical infectious diseases 27:23-27. 465 
11. Nielsen EI, Cars O, Friberg LE. 2011. Pharmacokinetic/pharmacodynamic (PK/PD) indices of 466 
antibiotics predicted by a semimechanistic PKPD model: a step toward model-based dose 467 
optimization. Antimicrobial agents and chemotherapy 55:4619-4630. 468 
12. Samiee-Zafarghandy S, van den Anker JN. 2013. Nephrotoxic effects of aminoglycosides on 469 
the developing kidney. Journal of Pediatric and Neonatal Individualized Medicine (JPNIM) 470 
2:e020227. 471 
13. Germovsek E, Barker CI, Sharland M. 2017. What do I need to know about aminoglycoside 472 
antibiotics? Archives of Disease in Childhood - Education and Practice 102:89-93. 473 
14. Etienne I, Joannides R, Dhib M, Fillastre JP. 1992. Drug-induced nephropathies. La Revue du 474 
praticien 42:2210-2216. 475 
15. Young TE. 2002. Aminoglycoside Therapy in Neonates. With Particular Reference to 476 
Gentamicin 3:e243-e248. 477 
16. Rao SC, Srinivasjois R, Hagan R, Ahmed M. 2011. One dose per day compared to multiple 478 
doses per day of gentamicin for treatment of suspected or proven sepsis in neonates. 479 
Cochrane Database of Systematic Reviews 11 Art. No.: CD005091. 480 
17. Joint Formulary Committee. 2015. Infection; Blood infection, bacterial. In: British National 481 
Formulary for Children. London: BMJ Group and Pharmaceutical Press, pp 274. 482 
18. Kent A, Turner MA, Sharland M, Heath PT. 2014. Aminoglycoside toxicity in neonates: 483 
something to worry about? Expert Review of Anti-infective Therapy 12:319-331. 484 
19. Germovsek E, Kent A, Metsvaht T, Lutsar I, Klein N, Turner MA, Sharland M, Nielsen EI, 485 
Heath PT, Standing JF. 2016. Development and Evaluation of a Gentamicin Pharmacokinetic 486 
Model That Facilitates Opportunistic Gentamicin Therapeutic Drug Monitoring in Neonates 487 
and Infants. Antimicrob Agents Chemother 60:4869-4877. 488 
20. Abitbol CL, DeFreitas MJ, Strauss J. 2016. Assessment of kidney function in preterm infants: 489 
lifelong implications. Pediatric Nephrology 31:2213-2222. 490 
20 
 
21. Fjalstad JW, Laukli E, van den Anker JN, Klingenberg C. 2013. High-dose gentamicin in 491 
newborn infants: is it safe? Eur J Pediatr 173:489-495. 492 
22. Allegaert K, van den Anker J. 2015. Neonatal drug therapy: The first frontier of therapeutics 493 
for children. Clin Pharmacol Ther 98:288-297. 494 
23. Hillman N, Kallapur SG, Jobe A. 2012. Physiology of Transition from intrauterine to 495 
Extrauterine Life. Clinics in perinatology 39:769-783. 496 
24. Ford S, Calvert J. 2008. Adaptation for life: a review of neonatal physiology. Anaesthesia & 497 
Intensive Care Medicine 9:93-98. 498 
25. Hartnoll G, Betremieux P, Modi N. 2000. Body water content of extremely preterm infants at 499 
birth. Archives of Disease in Childhood Fetal and Neonatal Edition 83:F56-F59. 500 
26. Metsvaht T, Nellis G, Varendi H, Nunn AJ, Graham S, Rieutord A, Storme T, McElnay J, 501 
Mulla H, Turner MA, Lutsar I. 2015. High variability in the dosing of commonly used 502 
antibiotics revealed by a Europe-wide point prevalence study: implications for research and 503 
dissemination. BMC Pediatr 15:41. 504 
27. Samardzic J, Allegaert K, Wilbaux M, Pfister M, van den Anker JN. 2016. Quantitative clinical 505 
pharmacology practice for optimal use of antibiotics during the neonatal period. Expert 506 
Opinion on Drug Metabolism & Toxicology 12:367-375. 507 
28. Wilbaux M, Fuchs A, Samardzic J, Rodieux F, Csajka C, Allegaert K, van den Anker JN, Pfister 508 
M. 2016. Pharmacometric Approaches to Personalize Use of Primarily Renally Eliminated 509 
Antibiotics in Preterm and Term Neonates. J Clin Pharmacol 56:909-935. 510 
29. 2015 Nelson's Pediatric Antimicrobial Therapy, 21st Edition. Edited by Bradley JS, Kimberlin 511 
DW. 512 
30. Spyridis N, Syridou G, Goossens H, Versporten A, Kopsidas J, Kourlaba G, Bielicki J, Drapier 513 
N, Zaoutis T, Tsolia M, Sharland M, Members APG. 2016. Variation in paediatric hospital 514 
antibiotic guidelines in Europe. Arch Dis Child 101:72-76. 515 
31. Pawluk S, Jaam M, Hazi F, Al Hail MS, El Kassem W, Khalifa H, Thomas B, Abdul Rouf P. 516 
2017. A description of medication errors reported by pharmacists in a neonatal intensive 517 
care unit. Int J Clin Pharm 39:88-94. 518 
32. Koumpagioti D, Varounis C, Kletsiou E, Nteli C, Matziou V. 2014. Evaluation of the 519 
medication process in pediatric patients: a meta-analysis. Jornal de Pediatria 90:344-355. 520 
33. The European Committee on Antimicrobial Susceptibility Testing. 2017.  Breakpoint tables 521 
for interpretation of MICs and zone diameters, version 7.1. 522 
http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Breakpoint_tables/v_7.1_B523 
reakpoint_Tables.pdf. Accessed 02-06-2017. 524 
34. Wayne PA. 2009. Clinical and Laboratory Standards Institute (CLSI) performance standards 525 
for antimicrobial disk diffusion susceptibility tests 19th ed. approved standard. CLSI 526 
document M100-S19 29. 527 
35. Woksepp H, Hällgren A, Borgström S, Kullberg F, Wimmerstedt A, Oscarsson A, Nordlund P, 528 
Lindholm ML, Bonnedahl J, Brudin L, Carlsson B, Schön T. 2017. High target attainment for 529 
β-lactam antibiotics in intensive care unit patients when actual minimum inhibitory 530 
concentrations are applied. European Journal of Clinical Microbiology & Infectious Diseases 531 
36:553-563. 532 
36. Kent A, Kortsalioudaki C, Monahan IM, Bielicki J, Planche TD, Heath PT, Sharland M. 2016. 533 
Neonatal gram-negative infections, antibiotic susceptibility and clinical outcome: an 534 
observational study. Arch Dis Child Fetal Neonatal Ed 101:F507-F512. 535 
37. Federal Office of Public Health and Federal Food Safety and Veterinary Office. 2016. Swiss 536 
Antibiotic Resistance Report 2016. Usage of Antibiotics and Occurrence of Antibiotic 537 
Resistance in Bacteria from Humans and Animals in Switzerland. Publication number: 2016-538 
OEG-30. 539 
38. Moore RD, Lietman PS, Smith CR. 1987. Clinical response to aminoglycoside therapy: 540 
importance of the ratio of peak concentration to minimal inhibitory concentration. Journal of 541 
Infectious Diseases 155:93-99. 542 
21 
 
39. Turnidge J. 2003. Pharmacodynamics and dosing of aminoglycosides. Infectious disease 543 
clinics of North America 17:503-528. 544 
40. Scheetz MH, Hurt KM, Noskin GA, Oliphant CM. 2006. Applying antimicrobial 545 
pharmacodynamics to resistant gram-negative pathogens. American Journal of Health-546 
System Pharmacy 63:1346-1360. 547 
41. Eliopoulos GM, Drusano GL, Ambrose PG, Bhavnani SM, Bertino JS, Nafziger AN, Louie A. 548 
2007. Back to the Future: Using Aminoglycosides Again and How to Dose Them Optimally. 549 
Clinical Infectious Diseases 45:753-760. 550 
42. Kashuba AD, Nafziger AN, Drusano GL, Bertino JS, Jr. 1999. Optimizing aminoglycoside 551 
therapy for nosocomial pneumonia caused by gram-negative bacteria. Antimicrob Agents 552 
Chemother 43:623-629. 553 
43. Strunk T, Richmond P, Simmer K, Currie A, Levy O, Burgner D. 2007. Neonatal immune 554 
responses to coagulase-negative staphylococci. Current Opinion in Infectious Diseases 555 
20:370-375. 556 
44. Mouton JW, Brown DFJ, Apfalter P, Cantón R, Giske CG, Ivanova M, MacGowan AP, Rodloff 557 
A, Soussy CJ, Steinbakk M, Kahlmeter G. 2012. The role of 558 
pharmacokinetics/pharmacodynamics in setting clinical MIC breakpoints: the EUCAST 559 
approach. Clinical Microbiology and Infection 18:E37-E45. 560 
45. Nielsen EI, Sandström M, Honoré PH, Ewald U, Friberg LE. 2009. Developmental 561 
Pharmacokinetics of Gentamicin in Preterm and Term Neonates. Clinical Pharmacokinetics 562 
48:253-263. 563 
46. Fuchs A, Guidi M, Giannoni E, Werner D, Buclin T, Widmer N, Csajka C. 2014. Population 564 
pharmacokinetic study of gentamicin in a large cohort of premature and term neonates. Br J 565 
Clin Pharmacol 78:1090-1101. 566 
47. DiCenzo R, Forrest A, Slish JC, Cole C, Guillet R. 2003. A Gentamicin Pharmacokinetic 567 
Population Model and Once-Daily Dosing Algorithm for Neonates. Pharmacotherapy: The 568 
Journal of Human Pharmacology and Drug Therapy 23:585-591. 569 
48. Frymoyer A, Meng L, Bonifacio SL, Verotta D, Guglielmo BJ. 2013. Gentamicin 570 
pharmacokinetics and dosing in neonates with hypoxic ischemic encephalopathy receiving 571 
hypothermia. Pharmacotherapy 33:718-726. 572 
49. Kelman AW, Thomson AH, Whiting B, Bryson SM, Steedman DA, Mawer GE, Samba‐Donga 573 
LA. 1984. Estimation of gentamicin clearance and volume of distribution in neonates and 574 
young children. British journal of clinical pharmacology 18:685-692. 575 
50. Lanao JM, Calvo MV, Mesa JA, Martin-Suarez A, Carbajosa MT, Miguelez F, Dominguez-Gil 576 
A. 2004. Pharmacokinetic basis for the use of extended interval dosage regimens of 577 
gentamicin in neonates. J Antimicrob Chemother 54:193-198. 578 
51. Stolk LML, Degraeuwe PLJ, Nieman FHM, de Wolf MC, de Boer A. 2002. Population 579 
Pharmacokinetics and Relationship Between Demographic and Clinical Variables and 580 
Pharmacokinetics of Gentamicin in Neonates. Therapeutic Drug Monitoring 24:527-531. 581 
52. García B, Barcia E, Pérez F, Molina IT. 2006. Population pharmacokinetics of gentamicin in 582 
premature newborns. Journal of Antimicrobial Chemotherapy 58:372-379. 583 
53. Bijleveld YA, de Haan TR, van der Lee HJH, Groenendaal F, Dijk PH, van Heijst A, de Jonge 584 
RCJ, Dijkman KP, van Straaten HLM, Rijken M, Zonnenberg IA, Cools F, Zecic A, Nuytemans 585 
DHGM, van Kaam AH, Mathot RAA, for the PharmaCool study g. 2016. Altered gentamicin 586 
pharmacokinetics in term neonates undergoing controlled hypothermia. British Journal of 587 
Clinical Pharmacology 81:1067-1077. 588 
54. Kumar A. 2014. An alternate pathophysiologic paradigm of sepsis and septic shock: 589 
Implications for optimizing antimicrobial therapy. Virulence 5:80-97. 590 
55. Yoshizawa K, Ikawa K, Ikeda K, Ohge H, Morikawa N. 2013. Population Pharmacokinetic–591 
Pharmacodynamic Target Attainment Analysis of Imipenem Plasma and Urine Data in 592 
Neonates and Children. The Pediatric Infectious Disease Journal 32:1208-1216. 593 
22 
 
56. Bradley JS, Sauberan JB, Ambrose PG, Bhavnani SM, Rasmussen MR, Capparelli EV. 2008. 594 
Meropenem Pharmacokinetics, Pharmacodynamics, and Monte Carlo Simulation in the 595 
Neonate. The Pediatric Infectious Disease Journal 27:794-799. 596 
57. Tremoulet A, Le J, Poindexter B, Sullivan JE, Laughon M, Delmore P, Salgado A, Ian-U Chong 597 
S, Melloni C, Gao J, Benjamin DK, Capparelli EV, Cohen-Wolkowiez M. 2014. 598 
Characterization of the Population Pharmacokinetics of Ampicillin in Neonates Using an 599 
Opportunistic Study Design. Antimicrobial Agents and Chemotherapy 58:3013-3020. 600 
58. Lopez SA, Mulla H, Durward A, Tibby SM. 2010. Extended-interval gentamicin: population 601 
pharmacokinetics in pediatric critical illness. Pediatr Crit Care Med 11:267-274. 602 
59. Quiros Y, Vicente-Vicente L, Morales AI, López-Novoa JM, López-Hernández FJ. 2011. An 603 
Integrative Overview on the Mechanisms Underlying the Renal Tubular Cytotoxicity of 604 
Gentamicin. Toxicological Sciences 119:245-256. 605 
60. Kent A, Turner MA, Sharland M, Heath PT. 2014. Aminoglycoside toxicity in neonates: 606 
something to worry about? Expert Rev Anti Infect Ther 12:319-331. 607 
61. Thomson AH, Kokwaro GO, Muchohi SN, English M, Mohammed S, Edwards G. 2003. 608 
Population pharmacokinetics of intramuscular gentamicin administered to young infants 609 
with suspected severe sepsis in Kenya. British Journal of Clinical Pharmacology 56:25-31. 610 
62. Rhodes A, Evans LE, Alhazzani W, Levy MM, Antonelli M, Ferrer R, Kumar A, Sevransky JE, 611 
Sprung CL, Nunnally ME. 2017. Surviving sepsis campaign: international guidelines for 612 
management of sepsis and septic shock: 2016. Intensive care medicine 43:304-377. 613 
63. Fuchs A, Zimmermann L, Bickle Graz M, Cherpillod J, Tolsa J-F, Buclin T, Giannoni E. 2016. 614 
Gentamicin Exposure and Sensorineural Hearing Loss in Preterm Infants. PLOS ONE 615 
11:e0158806. 616 
64. Shann F. 2008. Drug doses. Collective Pty Limited. 617 
65. Ainsworth SB. 2014. Neonatal formulary: drug use in pregnancy and the first year of life. 618 
John Wiley & Sons. 619 
66. Sharland M, Butler K, Cant A, Dagan R, Davies G, de Groot R, Elliman D, Esposito S, Finn A, 620 
Galanakis M. 2016. Manual of childhood infections: the blue book. Oxford University Press. 621 
67. Taketomo CK, Hodding JH, Kraus DM. 2013. Pediatric & neonatal dosage handbook: a 622 
comprehensive resource for all clinicians treating pediatric and neonatal patients. Lexi-comp. 623 
68. Report of the Committee on Infectious Diseases, 30th ed. In: Kimberlin DW, Bradley MT, 624 
Jackson MA, et al., eds. Red Book. Elk Grove Village, IL: American Academy of Pediatrics, 625 
2015. 626 
69. Thomas EY, Mangum B. 2010. Neofax 2010. Thomson Reuters. 627 
70. Versporten A, Bielicki J, Drapier N, Sharland M, Goossens H, Calle GM, Garrahan JP, Clark J, 628 
Cooper C, Blyth CC, Francis JR, Alsalman J, Jansens H, Mahieu L, Van Rossom P, Vandewal 629 
W, Lepage P, Blumental S, Briquet C, de Louvain C, Robbrecht D, Maton P, Gabriels P, Rubic 630 
Z, Kovacevic T, Nielsen JP, Petersen JR, Poorisrisak P, Jensen LH, Laan M, Tamm E, Matsinen 631 
M, Rummukainen M-L, Gajdos V, Olivier R, Le Maréchal F, Martinot A, Prot-Labarthe S, 632 
Lorrot M, Orbach D, Pagava K, Hufnagel M, Knuf M, Schlag SAA, Liese J, Renner L, Enimil A, 633 
Awunyo M, Syridou G, Spyridis N, et al. 2016. The Worldwide Antibiotic Resistance and 634 
Prescribing in European Children (ARPEC) point prevalence survey: developing hospital-635 
quality indicators of antibiotic prescribing for children. Journal of Antimicrobial 636 
Chemotherapy 71:1106-1117. 637 
71. Versporten A, Sharland M, Bielicki J, Drapier N, Vankerckhoven V, Goossens H. 2013. The 638 
Antibiotic Resistance and Prescribing in European Children Project: A Neonatal and Pediatric 639 
Antimicrobial Web-based Point Prevalence Survey in 73 Hospitals Worldwide. The Pediatric 640 
Infectious Disease Journal 32:e242-e253. 641 
72. Lingvall M, Reith D, Broadbent R. 2005. The effect of sepsis upon gentamicin 642 
pharmacokinetics in neonates. British journal of clinical pharmacology 59:54-61. 643 
73. Botha JH, du Preez MJ, Adhikari M. 2003. Population pharmacokinetics of gentamicin in 644 
South African newborns. Eur J Clin Pharmacol 59:755-759. 645 
23 
 
74. Weber W, Kewitz G, Rost KL, Looby M, Nitz M, Harnisch L. 1993. Population kinetics of 646 
gentamicin in neonates. European journal of clinical pharmacology 44:S23-S25. 647 
75. Thomson AH, Way S, Bryson SM, McGovern EM, Kelman AW, Whiting B. 1988. Population 648 
pharmacokinetics of gentamicin in neonates. Developmental pharmacology and therapeutics 649 
11:173-179. 650 
76. Jensen PD, Edgren BE, Brundage RC. 1992. Population Pharmacokinetics of Gentamicin in 651 
Neonates Using a Nonlinear, Mixed‐Effects Model. Pharmacotherapy: The Journal of Human 652 
Pharmacology and Drug Therapy 12:178-182. 653 
77. Sherwin CM, Kostan E, Broadbent RS, Medlicott NJ, Reith DM. 2009. Evaluation of the effect 654 
of intravenous volume expanders upon the volume of distribution of gentamicin in septic 655 
neonates. Biopharm Drug Dispos 30:276-280. 656 
78. Bijleveld YA, van den Heuvel ME, Hodiamont CJ, Mathôt RAA, de Haan TR. 2017. Population 657 
Pharmacokinetics and Dosing Considerations for Gentamicin in Newborns with Suspected or 658 
Proven Sepsis Caused by Gram-Negative Bacteria. Antimicrobial Agents and Chemotherapy 659 
61:e01304-01316. 660 
79. Rhodin MM, Anderson BJ, Peters AM, Coulthard MG, Wilkins B, Cole M, Chatelut E, Grubb 661 
A, Veal GJ, Keir MJ, Holford NHG. 2008. Human renal function maturation: a quantitative 662 
description using weight and postmenstrual age. Pediatric Nephrology 24:67. 663 
 664 
 665 
Figure 1: Percentage of neonates with target peak concentrations for various gentamicin 666 
doses per kg of body weight after first dose for entire neonatal population. Tested target peak 667 
concentrations ≥ 5, ≥ 10, ≥ 20, ≥ 40 mg/L corresponding to MICs of 0.5, 1.0, 2.0 or 4.0 mg/L 668 
respectively. 669 
 670 
Figure 2: Distribution of peak and trough concentration after single 7.5 mg/kg gentamicin 671 
dose for four subgroups over 48h interval (PNA < 7 days or PNA ≥ 7 days & GA ≤ 28 weeks) 672 
or 36h interval (PNA ≥ 7 days & GA > 28 weeks). PNA; post-natal age, GA; gestational age. 673 
Boxes represent the interquartile range (IQR), solid lines are the median, 25
th
 and 75
th
 674 
quantile and whiskers equal 25
th
 quantile -1.5 IQR and 75
th
 quantile + 1.5 IQR. 675 
 676 
  
 
 
Table 1: Probability of target attainment for guidelines and Swiss centers for effective peak 
concentration (≥ 5 or ≥ 10 mg/L) and trough concentration > 2 mg/L.  
* Subgroups are based on demographic characteristics as indicated in guidelines.  
† Guidelines suggested a dosing interval range of 24 – 48 hours and therapeutic drug 
monitoring was recommended after first dose.  
BNFc; British National Formulary for Children, Blue Book; Manual of childhood 
infections Blue Book, Nelson; Nelson Textbook of Pediatrics, NNF7; Neonatal Formulary 
7th edition, Lexicomp; Lexicomp Pediatric & Neonatal Dosage Handbook, Red Book; Red 
Book report of the Committee on Infectious Diseases, Shann; Frank Shann Drug Doses, 
PNA; postnatal age, GA; gestational age, WT; weight, PMA; postmenstrual age.  
 
 
Guideline Demographic 
characteristics 
Dose 
(mg/kg) 
Interval 
(hours) 
No. of 
subgroups* 
Targets (mg/L) 
Peak (%) Trough (%) 
≥ 5 ≥ 10 > 2 
   No demographic variable 
Center 5 - 4 24 1 96 26 4 
Center 7 (1) †  - 5 24 1 99 54 12 
Center 7 (2) † - 5 36 1 99 54 < 0.5 
Center 7 (3) † - 5 48 1 99 54 < 0.5 
   One demographic variable 
BNFc  PNA 5 24 / 36 2 99 54 3 
Blue Book (min)  GA 4 24 / 36 2 96 26 1  
Blue Book (max)  GA 5 24 / 36 2 99 54 4  
   Two demographic variables 
Center 1 PNA & WT 4 / 5 24 – 48 5 97 39 2 
Center 2 PNA & WT 5 / 6 24 – 48 7 99 58 4 
Center 3 (min)  PNA & GA 4 / 5 24 – 48 6 96 28 1  
Center 3 (max)  PNA & GA 5 24 – 48 6 99 54 4 
Center 4  PNA & PMA 4 / 4.5 / 5 24 – 48 6 96 30 2 
Center 6  PNA & GA 4 / 4.5 / 5 24 – 48 6 96 30 1 
Nelson  PNA & GA 4 / 4.5 / 5 24 – 48 7 97 37 1 
NNF7  PNA & GA 5 24 – 48 4 99 55 5 
Lexicomp PNA & GA 4 / 4.5 / 5 24 – 48 6 98 43 1 
Red Book (min) PNA & WT 4 / 5 24 – 48 6 97 39 2 
Red Book (max)  PNA & WT 4 / 5 24 – 48 6 98 44 2 
Neofax  PNA & PMA 4 / 4.5 / 5 24 – 48 5 96 30 1 
Shann  PNA & WT 5 / 6 24 – 48 7 99 58 4 
  
 
 
 GA = 30 weeks GA = 38 weeks 
PNA: 2 days 
WT: 1.3 kg 
PNA: 15 days 
WT: 1.5 kg 
PNA: 2 days 
WT: 3.0 kg 
PNA: 15 days 
WT: 3.3 kg 
Nelson 5 mg/kg * 48h 4 mg/kg * 24h 4 mg/kg * 24h 4 mg/kg * 24h 
BNFc 5 mg/kg * 36h 5 mg/kg * 24h 5 mg/kg * 36h 5 mg/kg * 24h 
Shann 5 mg/kg * 36h 5 mg/kg * 24h 5 mg/kg * 24h 6 mg/kg * 24h 
Lexicomp 4.5 mg/kg * 36h 5 mg/kg * 36h 4 mg/kg * 24h 5 mg/kg * 24h 
Center 1 5 m/kg * 48h 5 mg/kg * 36h 4 mg/kg * 24h 4 mg/kg * 24h 
Center 3 4-5 mg/kg * 36h 4-5 mg/kg * 24h 4-5 mg/kg * 24h 4-5 mg/kg * 24h  
Center 6 4.5 mg/kg * 36h 4 mg/kg * 24h 4 mg/kg * 24h 4 mg/kg * 24h 
Center 7 5 mg/kg * 24-48h 5 mg/kg * 24-48h 5 mg/kg * 24-48h 5 mg/kg * 24-48h 
 
 
Table 2: Variability in gentamicin dosing recommendations for two typical patients. GA; 
gestational age, PNA; postnatal age, WT; body weight, h; hours, *; every, Nelson; 
Nelson’s Pediatric Antimicrobial Therapy handbook, Shann; Frank Shann, Lexicomp; 
Lexicomp Pediatric & Neonatal Dosage Handbook, Center; Swiss neonatal and pediatric 
centers. 
 
 
 
 
 
 First dose After 1 Week of Treatment 
Dosing Regimen Demographic 
Characteristics  
% Neonates 
with ratio 
Peak/MIC  
% Neonates                           
with Trough  
% Neonates 
with ratio 
Peak/MIC  
% Neonates 
with Trough  
> 10  < 1 mg/L < 2 mg/L > 10  < 1 mg/L  < 2 mg/L 
     MIC 0.5 mg/L        
4 mg/kg * 36h PNA < 7 & GA ≤ 28 98 62 100 98 43 94 
4 mg/kg * 36h PNA < 7 & GA > 28 97 91 100 97 86 99 
4 mg/kg * 36h PNA ≥ 7 & GA ≤ 28 96 88 100 97 70 96 
4 mg/kg * 24h PNA ≥ 7 & GA > 28 94 80 99 95 65 93 
     MIC 1.0 mg/L        
7.5 mg/kg * 48h PNA < 7 & GA ≤ 28 98 40 98 98 38 87† 
7.5 mg/kg * 48h PNA < 7 & GA > 28 91 85 99 92 84 97 
7.5 mg/kg * 48h PNA ≥ 7 & GA ≤ 28 95 81 99 95 67 92 
7.5 mg/kg * 36h PNA ≥ 7 & GA > 28 90 83 99 91 74 95 
 
Table 3: Probability of target attainment for pre-defined peak and trough concentration targets following optimal dosing regimen (administration 
of 7.5 mg/kg over different dosing interval according to patients characteristics). MIC; Minimum Inhibition Concentration, PNA; Post-natal age 
(days). GA; Gestational age (weeks).† To achieve a PTA of 90% would require a dosing interval of 60h (PTA = 97%). After second dose with a 
dosing interval of 48h (96 hours after the start of treatment), PTA would still be of 93%. 
 
 
 
 
Number of Neonates  N (%) 
   Total population 1071 (100 %) 
   Preterm (GA < 37 weeks) 654 (58 %) 
   Preterm (GA < 28 weeks) 201 (18 %) 
Demographic Characteristics  Median (min – max) 
   Gestational age (weeks) 34 (22 – 44) 
   Birth weight (kg) 2.1 (0.4 – 4.8) 
   Post-natal age (days) 7 (0 – 60) 
     ≤ 7 days (%) 54 % 
   Current weight (kg) 2.2 (0.48 – 4.86) 
   Post menstrual age (weeks) 35.7 (23.7 – 47.6) 
 
Table 4: Demographic characteristics from the Antibiotic Resistance and Prescribing in 
European Children data subset used for exposure simulation. GA; gestational age, kg; 
kilograms. 
 
 


